Bevacizumab (& biosimilars)

BNF:
Immune System & Malignant Disease
Status:
Do Not Prescribe (DNP)
Decision Date:
None
 

Comments

DO NOT PRESCRIBE (DNP): 

  • NICE TA242: Colorectal cancer (metastatic) 2nd line. Bevacizumab - not recommended with fluoropyrimidines.  (Decision date - February 2012).

  • NICE TA263: in combination with capecitabine for the first line treatment of metastatic breast cancer.  (Negative appraisal).  (Decision date - September 2012).
  • NICE TA284: in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer.  (Decision date - July 2013).
  • NICE TA285: in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer.  (Decision date - July 2013).
  • NICE TA353: for treating relapsed platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.  (Terminated appraisal).  (Decision date - September 2015).
  • NICE TA436: for treating EGFR mutation-positive non-small-cell lung cancer.  (Terminated appraisal).  (Decision date - April 2017).
  • NICE TA560: treating the first occurrence of platinum-sensitive advanced ovarian cancer.  (Terminated appraisal).  (Decision date - March 2019)

This drug may be funded through the cancer drug fund - seek advice from the oncologist/haematologist/ NHS England.

 

Do Not Prescribe (DNP) Drug Classifications

  • 6: Have NICE guidance that recommends they should not be used

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app